Skip to main content
Premium Trial:

Request an Annual Quote

Labs Fournier to Use Temis' Text Mining Software for Biomarker Research

NEW YORK (GenomeWeb News) – Software maker Temis said today that Laboratoires Fournier, a drug discovery affiliate of Solvay Pharmaceuticals, will use Temis’ Luxid text analytic solution.
 
Laboratoires Fournier will use the software in its Exploratory Biology Unit, which searches for biomarkers that could be used in Solvay’s pre-clinical drug development programs.
 
Temis said it began a partnership with Laboratoires Fournier in 2005 that involved using Luxid for synthesis of biological, medical, and chemical information, and that it now plans to develop an information extraction tool for discovering biomarkers.
 
Financial terms of the agreement were not released.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.